HC Wainwright Boosts Earnings Estimates for Nuvation Bio

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Nuvation Bio to a loss of $0.13 per share from a previous loss estimate of $0.14, while maintaining a “Buy” rating and $21 price target.
• Analyst sentiment is generally positive, with Nuvation Bio receiving a “Moderate Buy” consensus rating from 11 analysts and an average target price of $12.88. The stock recently opened at $6.69, well below its 12-month high of $9.75.
• Nuvation Bio beat its latest quarterly EPS expectations, reporting $0.01 versus the projected loss of $0.03, while revenue of $83.23 million exceeded estimates of $66.22 million. Institutional investors own 61.67% of the company, though insiders sold 235,668 shares over the past 90 days.

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for Nuvation Bio in a report issued on Monday, July 27th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.14). HC Wainwright has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for Nuvation Bio's Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.30) EPS.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a "sell (d-)" rating on shares of Nuvation Bio in a research note on Friday, July 17th. Zacks Research raised shares of Nuvation Bio from a "strong sell" rating to a "hold" rating in a research report on Monday, July 6th. Truist Financial upped their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, July 7th. Royal Bank Of Canada reissued an "outperform" rating on shares of Nuvation Bio in a research report on Wednesday, July 22nd. Finally, Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Nuvation Bio in a research note on Thursday, July 23rd. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nuvation Bio has a consensus rating of "Moderate Buy" and an average target price of $12.88.

Nuvation Bio Stock Performance

Shares of NYSE NUVB opened at $6.69 on Wednesday. The company has a current ratio of 7.44, a quick ratio of 7.24 and a debt-to-equity ratio of 0.15. Nuvation Bio has a 12 month low of $2.18 and a 12 month high of $9.75. The stock has a 50 day moving average of $5.49 and a 200-day moving average of $5.25. The company has a market capitalization of $2.33 billion, a P/E ratio of -15.56 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.04. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%.The firm had revenue of $83.23 million for the quarter, compared to analyst estimates of $66.22 million.

Insider Transactions at Nuvation Bio

In other news, Director Robert Mashal purchased 25,000 shares of Nuvation Bio stock in a transaction that occurred on Tuesday, June 9th. The stock was acquired at an average cost of $4.73 per share, for a total transaction of $118,250.00. Following the purchase, the director directly owned 225,000 shares of the company's stock, valued at $1,064,250. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Stacy Markel sold 125,000 shares of the company's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.03, for a total value of $753,750.00. Following the completion of the transaction, the insider directly owned 32,591 shares in the company, valued at approximately $196,523.73. This represents a 79.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 235,668 shares of company stock valued at $1,419,495. 30.11% of the stock is currently owned by company insiders.

Institutional Trading of Nuvation Bio

A number of institutional investors have recently bought and sold shares of NUVB. Vanguard Group Inc. increased its holdings in shares of Nuvation Bio by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company's stock worth $139,378,000 after purchasing an additional 101,011 shares during the period. Millennium Management LLC boosted its stake in shares of Nuvation Bio by 52.4% in the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock valued at $6,642,000 after buying an additional 1,298,131 shares during the period. Dimensional Fund Advisors LP grew its position in Nuvation Bio by 19.9% during the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company's stock worth $12,276,000 after buying an additional 551,508 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Nuvation Bio by 852.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company's stock worth $24,270,000 after buying an additional 2,424,109 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in Nuvation Bio by 95.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company's stock worth $8,797,000 after acquiring an additional 1,162,837 shares during the period. Institutional investors own 61.67% of the company's stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.